+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Pharmaceutical and Healthcare Industry in China - Forecast and Analysis 2021

  • PDF Icon

    Report

  • 215 Pages
  • August 2021
  • Region: China
  • Aruvian Research
  • ID: 5395381
The COVID-19 pandemic has had quite an impact on the Chinese pharmaceutical and healthcare industry, through industry analysts expect a speedy recovery back to normal levels of demand. The Chinese pharmaceutical and healthcare industry is one of the largest markets in the world, and it is well on its way to becoming a leading global hub for drug innovation and drug development. Even as the COVID-19 crisis rages on, there is an increasing international investment in the Chinese pharma and healthcare sectors.

China's healthcare and pharmaceutical landscape is looking at promising new healthcare reforms in the coming years as the government looks to provide quality healthcare to its population's increasing demand. On March 5, 2021, the government announced institutional healthcare reforms in line with China's 14th Five Year Plan (2021-2025).

The government has also highlighted a detailed roadmap for enhancing the overall quality of healthcare in the country while also expanding the necessary services in this sector. With generic drugs being the mainstay of the country's population, generics accounted for nearly 65% of the overall pharmaceutical industry in 2020. While growth in the pharmaceutical industry is unlikely to return to pre-pandemic highs, China will continue to remain one of the biggest markets for drugmakers worldwide.

The publisher presents an in-depth analysis of the Pharmaceutical and Healthcare Industry of China in its research report Pharmaceutical and Healthcare Industry in China – Forecast and Analysis 2021.

The report covers the following data:

  • An in-depth coverage of the pharmaceutical and healthcare industry in China by sectors along with an analysis of how the COVID-19 pandemic is effecting the industry.
  • We analyze the segments of prescription drugs, generic drugs, OTC medicines, and also analyze the landscape for medical research and clinical trials in China.
  • A SWOT analysis of the Chinese pharmaceutical and healthcare industry.
  • A Porter's Five Forces Strategic Analysis of the Chinese pharmaceutical and healthcare Industry is included that looks at the bargaining power of buyers and suppliers, competitive rivalry in the industry, and the threat of new entrants and industry substitution.
  • We take an up-close view of the regulatory framework governing the Chinese pharmaceutical and healthcare industry, and the challenges being faced in terms of intellectual property rights. An analysis of China's 14th Five-Year Plan for Healthcare Reforms is also included in this section.
  • Competition in the industry, along with an in-depth analysis of the both the domestic and multinational players in the sector like Shanghai Pharmaceuticals Holding, Sinopharm Group, Tasly Pharmaceutical Group, China Shijiazhuang Pharmaceutical Group, AstraZeneca, Eli Lilly (Lilly China), Novartis, and many others are included.

A detailed forecast of the Chinese pharmaceutical and healthcare industry by segments completes this comprehensive analysis.

Table of Contents


A. Executive SummaryB. Industry DefinitionC. Brief View of the APAC Pharmaceutical & Healthcare Sector
D. Pharmaceutical & Healthcare Industry in China
D.1 Impact of COVID-19 on the Industry
D.2 Pharmaceutical Sector Analysis
D.3 Healthcare Sector Analysis
D.4 Market for Prescription Drugs
D.5 Market for Patented Drugs
D.6 Market for OTC Medicines
D.7 Market for Generic Drugs
D.8 Medical Research & Clinical Trials in China


E. Pharmaceutical & Healthcare Industry in China: SWOT Analysis
E.1 Strengths to Build Upon
E.2 Weaknesses to Overcome
E.3 Opportunities to Exploit
E.4 Threats to Overcome


F. China Pharmaceutical Industry: Porter’s Five Forces Strategy Analysis
F.1 Overview
F.2 Bargaining Power of Buyers
F.3 Bargaining Power of Suppliers
F.4 Competitive Rivalry in the Industry
F.5 Threat of New Entrants
F.6 Threat of Substitutes


G. Chronic Medical Conditions in China
G.1 Overview
G.2 Cancer
G.3 Chronic Obstructive Pulmonary Disease
G.4 Diabetes


H. Regulatory Framework of the Industry
H.1 Overview
H.2 China's 14th Five-Year Plan for Healthcare Reforms
H.3 Regulations Governing OTC Drugs
H.4 Regulations Governing Biosimilars
H.5 Challenges with Intellectual Property Rights
H.6 Challenges with Counterfeit Medications
H.7 Pricing & Reimbursement Regime
H.8 Regulations Governing Marketing of Pharmaceuticals


I. Import/Export of Pharmaceuticals in China
J. Competition in the Industry
J.1 Competitive Landscape
J.2 Competition in Generic Drugs
J.3 Competition in the Pharmacy Sector
J.4 Competition in Drug Distribution


K. Forecast: Pharmaceutical & Healthcare Industry in China
K.1 Outlook of the Chinese Pharmaceutical Industry
K.2 Outlook of the Chinese Healthcare Industry
K.3 Outlook for Prescription Drugs Sector
K.4 Outlook for Patented Drugs Market
K.5 Outlook for OTC Medicine Market
K.6 Outlook for the Generic Drugs Market


L. Major Domestic & Multinational Players
L.1 China Shijiazhuang Pharmaceutical Group
L.1.1 Corporate Analysis
L.1.2 Business Segment Analysis
L.1.3 Financial Analysis
L.1.4 SWOT Analysis
L.2 Jiangsu Hengrui Medicine Co. Ltd.
L.2.1 Corporate Analysis
L.2.2 Business Segment Analysis
L.2.3 Financial Analysis
L.2.4 SWOT Analysis
L.3 Nanjing Pharmaceutical
L.3.1 Corporate Analysis
L.3.2 Business Segment Analysis
L.3.3 Financial Analysis
L.3.4 SWOT Analysis
L.4 North China Pharmaceutical Corporation
L.4.1 Corporate Analysis
L.4.2 Business Segment Analysis
L.4.3 Financial Analysis
L.4.4 SWOT Analysis
L.5 Shanghai Pharmaceuticals Holding Co.
L.5.1 Corporate Analysis
L.5.2 Business Segment Analysis
L.5.3 Financial Analysis
L.5.4 SWOT Analysis
L.6 Sinopharm Group
L.6.1 Corporate Analysis
L.6.2 Business Segment Analysis
L.6.3 Financial Analysis
L.6.4 SWOT Analysis
L.7 Tasly Pharmaceutical Group
L.7.1 Corporate Analysis
L.7.2 Business Segment Analysis
L.7.3 Financial Analysis
L.7.4 SWOT Analysis
L.8 AstraZeneca
L.8.1 Corporate Analysis
L.8.2 Business Segment Analysis
L.8.3 Financial Analysis
L.8.4 SWOT Analysis
L.9 Bayer Healthcare
L.9.1 Corporate Analysis
L.9.2 Business Segment Analysis
L.9.3 Financial Analysis
L.9.4 SWOT Analysis
L.10 Eli Lilly and Co. (Lilly China)
L.10.1 Corporate Analysis
L.10.2 Business Segment Analysis
L.10.3 Financial Analysis
L.10.4 SWOT Analysis
L.11 GlaxoSmithKline
L.11.1 Corporate Analysis
L.11.2 Business Segment Analysis
L.11.3 Financial Analysis
L.11.4 SWOT Analysis
L.12 Merck & Co.
L.12.1 Corporate Analysis
L.12.2 Business Segment Analysis
L.12.3 Financial Analysis
L.12.4 SWOT Analysis
L.13 Novartis
L.13.1 Corporate Analysis
L.13.2 Business Segment Analysis
L.13.3 Financial Analysis
L.13.4 SWOT Analysis
L.14 Pfizer
L.14.1 Corporate Analysis
L.14.2 Business Segment Analysis
L.14.3 Financial Analysis
L.14.4 SWOT Analysis
L.15 Roche
L.15.1 Corporate Analysis
L.15.2 Business Segment Analysis
L.15.3 Financial Analysis
L.15.4 SWOT Analysis
L.16 Sanofi SA
L.16.1 Corporate Analysis
L.16.2 Business Segment Analysis
L.16.3 Financial Analysis
L.16.4 SWOT Analysis
L.17 China Grand Pharmaceutical and Healthcare Holdings Ltd
L.18 China Resources Pharmaceutical Group Ltd.
L.19 Harbin Pharmaceutical Group
L.20 Jiangsu Simcere Pharmaceutical Co. Ltd.
L.21 Luye Pharma Group Ltd.
L.22 Shanghai Fosun Pharmaceutical (Group) Co Ltd
L.23 Shijiazhuang Yiling Pharmaceutical Co Ltd
L.24 Sihuan Pharmaceutical Holdings Group Ltd.
L.25 Sino Biopharmaceutical Limited
L.26 Sundia MediTech Co. Ltd.
L.27 Zhejiang Hisun Pharmaceutical


M. Glossary of TermsN. Research MethodologyO. Disclaimer
List of Figures
Figure 1: Outpatient Decline during the COVID-19 Outbreak in China
Figure 2: New Drug Approvals in China during peak of the Pandemic, 2020 vs 2021
Figure 3: Growth of the Pharmaceutical Sales in China, 2016-2030
Figure 4: Clinical Trial Registrations in China, 2016-2019
Figure 5: Porter's Five Forces Analysis of the Chinese Pharmaceutical Industry
Figure 6: Bargaining Power of Buyers in the Chinese Pharmaceutical Industry
Figure 7: Bargaining Power of Suppliers in the Chinese Pharmaceutical Industry
Figure 8: Competitive Rivalry in the Chinese Pharmaceutical Industry
Figure 9: Threat of New Entrants to the Chinese Pharmaceutical Industry
Figure 10: Threat of Substitutes to the Chinese Pharmaceutical Industry
Figure 11: Positive Impact of Healthcare Reforms on Pharmaceutical Sales in China (in CNY billion), 2019-2030
Figure 12: Import-Export of Pharmaceuticals in China (in CNY Million), 2016-2025
Figure 13: Expenditure on Healthcare in China, 2017-2025
Figure 14: Forecast of the Prescription Drug Market in China, 2016-2030
Figure 15: Forecast of the Patented Drugs Sector in China, 2016-2030
Figure 16: Forecast of the OTC Medicine Market in China, 2016-2030
Figure 17: Forecast of the Generic Drug Market in China, 2016-2030


List of Tables
Table 1: Growth of the Pharmaceutical Sales in China, 2017-2025
Table 2: Healthcare Resources in China, 2015-2020
Table 3: Inpatient/Outpatient Statistics in China, 2015-2020
Table 4: Personnel Employed in the Healthcare Sector in China, 2015-2020
Table 5: Import-Export of Pharmaceuticals in China (in CNY Million), 2019-2025
Table 6: Import-Export of Pharmaceuticals in China (in USD Million), 2019-2025
Table 7: Statistics of the Pharmaceutical & Healthcare Industry in China, 2019-2025
Table 9: Government Expenditure on Healthcare in China, 2017-2025
Table 10: Healthcare Expenditure by Private Sector on Healthcare in China, 2017-2025
Table 11: Forecast of the Prescription Drug Market in China, 2017-2025
Table 12: Forecast of the Patented Drugs Sector in China, 2017-2025
Table 13: Forecast of the OTC Medicine Market in China, 2016-2030
Table 14: Forecast of the Generic Drug Market in China, 2017-2025

Companies Mentioned

  • China Grand Pharmaceutical and Healthcare Holdings Ltd
  • China Resources Pharmaceutical Group Ltd.
  • China Shijiazhuang Pharmaceutical Group
  • Harbin Pharmaceutical Group
  • Jiangsu Hengrui Medicine Co. Ltd.
  • Jiangsu Simcere Pharmaceutical Co. Ltd.
  • Luye Pharma Group Ltd.
  • Nanjing Pharmaceutical
  • North China Pharmaceutical Corporation
  • Shanghai Fosun Pharmaceutical (Group) Co Ltd
  • Shanghai Pharmaceuticals Holding Co.
  • Shijiazhuang Yiling Pharmaceutical Co Ltd
  • Sihuan Pharmaceutical Holdings Group Ltd.
  • Sino Biopharmaceutical Limited
  • Sinopharm Group
  • Sundia MediTech Co. Ltd.
  • Tasly Pharmaceutical Group
  • Zhejiang Hisun Pharmaceutical
  • AstraZeneca
  • Bayer Healthcare
  • Eli Lilly and Co. (Lilly China)
  • GlaxoSmithKline
  • Merck & Co.
  • Novartis
  • Pfizer
  • Roche
  • Sanofi SA